Designing Drug Development Programs for Reimbursement Success
Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…
CertaraMay 7, 2026
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…
CertaraMay 7, 2026
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…
CertaraMay 7, 2026
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies
Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…
CertaraMay 7, 2026
Optimize Readiness for MHRA-NICE Aligned Pathway
Achieve HTA and regulatory success in the MHRA–NICE pathway through early evidence alignment.
CertaraMay 1, 2026
Compliance? Anywhere, anytime: Automated controlled substance detection and tariff classification at Merck KGaA
Learn how Merck KGaA automates controlled substance detection and HS classification to ensure global compliance…
CertaraApril 27, 2026
DIDB® Concomitant Meds Navigator
Explore the Concomitant Meds Navigator withing DIDB - An evidence-based tool within DIDB that helps…
CertaraApril 27, 2026
ADC Dose Optimization: Applying Model-Informed Strategies in Development
Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…
CertaraApril 22, 2026
